|
The Role of Public– WORKSHOP SUMMARY |
Rachel M. Taylor and Jennifer Christian, Rapporteurs
Forum on Public–Private Partnerships for Global Health and Safety
Board on Global Health
Institute of Medicine
THE NATIONAL ACADEMIES PRESS
Washington, DC
THE NATIONAL ACADEMIES PRESS 500 Fifth Street, NW Washington, DC 20001
Financial support for this activity was provided by Anheuser-Busch InBev; Becton, Dickinson and Company; The Bill & Melinda Gates Foundation; CARE USA; Catholic Health Association of the United States; e-Development International; Estée Lauder Companies; ExxonMobil; Fogarty International Center of the National Institutes of Health; GE; Global Health Innovative Technology Fund; Johnson & Johnson; Lockheed Martin Corporation; Medtronic; Merck; Novartis Foundation; PATH; PepsiCo; Pfizer, Inc.; Procter & Gamble Co.; The Rockefeller Foundation; Takeda Pharmaceuticals; United Nations Foundation; University of Notre Dame; UPS Foundation; U.S. Agency for International Development; U.S. Department of Health and Human Services Office for Global Affairs; U.S. Department of State/Office of the Global AIDS Coordinator; U.S. Food and Drug Administration; Verizon Foundation; and The Vitality Group. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.
International Standard Book Number-13: 978-0-309-38139-0
International Standard Book Number-10: 0-309-38139-8
Digital Object Identifier: 10.17226/21861
Additional copies of this workshop summary are available for sale from the National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624-6242 or (202) 334-3313; http://www.nap.edu.
Copyright 2016 by the National Academy of Sciences. All rights reserved.
Printed in the United States of America
Suggested citation: National Academies of Sciences, Engineering, and Medicine. 2016. The role of public–private partnerships in health systems strengthening: Workshop summary. Washington, DC: The National Academies Press. doi: 10.17226/21861.
The National Academy of Sciences was established in 1863 by an Act of Congress, signed by President Lincoln, as a private, nongovernmental institution to advise the nation on issues related to science and technology. Members are elected by their peers for outstanding contributions to research. Dr. Ralph J. Cicerone is president.
The National Academy of Engineering was established in 1964 under the charter of the National Academy of Sciences to bring the practices of engineering to advising the nation. Members are elected by their peers for extraordinary contributions to engineering. Dr. C. D. Mote, Jr., is president.
The National Academy of Medicine (formerly the Institute of Medicine) was established in 1970 under the charter of the National Academy of Sciences to advise the nation on medical and health issues. Members are elected by their peers for distinguished contributions to medicine and health. Dr. Victor J. Dzau is president.
The three Academies work together as the National Academies of Sciences, Engineering, and Medicine to provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions. The Academies also encourage education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science, engineering, and medicine.
Learn more about the National Academies of Sciences, Engineering, and Medicine at www.national-academies.org.
This page intentionally left blank.
PLANNING COMMITTEE ON THE LONG-TERM PICTURE FOR HEALTH SYSTEMS: THE ROLE OF PUBLIC–PRIVATE PARTNERSHIPS IN HEALTH SYSTEMS STRENGTHENING1
SIMON BLAND (Co-Chair), Director, New York Liaison Office, Joint United Nations Programme on HIV/AIDS
KATHERINE BOND (Co-Chair), Director, Office of Strategy, Partnerships, and Analytics, U.S. Food and Drug Administration (until November 2015); Vice President, International Regulatory Affairs; U.S. Pharmacopeia (since November 2015)
ROBERT BOLLINGER, Professor of Medicine, Public Health and Nursing, Johns Hopkins University School of Medicine
JO IVEY BOUFFORD, President, New York Academy of Medicine
BRUCE COMPTON, Senior Director of International Outreach, Catholic Health Association of the United States
TREVOR GUNN, Vice President, International Relations, Medtronic
___________________
1 The National Academies of Sciences, Engineering, and Medicine’s planning committees are solely responsible for organizing the workshop, identifying topics, and choosing speakers. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.
This page intentionally left blank.
FORUM ON PUBLIC–PRIVATE PARTNERSHIPS FOR GLOBAL HEALTH AND SAFETY1
JO IVEY BOUFFORD (Co-Chair), President, New York Academy of Medicine
CLARION JOHNSON (Co-Chair), Private Consultant, ExxonMobil
ANN AERTS, Head, Novartis Foundation (from January 2016)
TARA ACHARYA, Senior Director, Strategic Nutrition Risks in Global R&D, PepsiCo (until April 2016)
SIR GEORGE ALLEYNE, Director Emeritus, Pan American Health Organization; Chancellor, University of the West Indies
RAJESH ANANDAN, Senior Vice President, Strategic Partnerships and UNICEF Ventures, U.S. Fund for UNICEF
MARLEECE BARBER, Director of Health and Wellness and Chief Medical Officer, Lockheed Martin Corporation
DEBORAH L. BIRX, Ambassador-at-Large; U.S. Global AIDS Coordinator and U.S. Special Representative for Global Health Diplomacy (from November 2015)
SIMON BLAND, Director, New York Liaison Office, Joint United Nations Programme on HIV/AIDS
ROBERT BOLLINGER, Professor of Medicine, Public Health and Nursing, Johns Hopkins University School of Medicine
KIM C. BUSH, Director, Life Sciences Partnerships, Global Health Program, The Bill & Melinda Gates Foundation
GARY M. COHEN, Executive Vice President and President, Global Health and Development, Becton, Dickinson and Company
BRENDA D. COLATRELLA, Executive Director, Corporate Responsibility, President, Merck Foundation, Merck
BRUCE COMPTON, Senior Director of International Outreach, Catholic Health Association of the United States
PATRICIA DALY, Senior Director, Save the Children
PATRICIA J. GARCIA, Dean, School of Public Health, Cayetano Heredia University
HELENE D. GAYLE, President and Chief Executive Officer, CARE USA (until July 2015)
ELAINE GIBBONS, Executive Director, Corporate Engagement, PATH
ROGER GLASS, Director, Fogarty International Center
LOUISE GRESHAM, President and Chief Executive Officer, Fondation Mérieux USA (until January 2015)
___________________
1 The National Academies of Sciences, Engineering, and Medicine’s forums and roundtables do not issue, review, or approve individual documents. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.
RICHARD GUERRANT, Thomas H. Hunter Professor of International Medicine, University of Virginia
TREVOR GUNN, Vice President, International Relations, Medtronic
JESSICA HERZSTEIN, Member, U.S. Preventive Services Task Force
BEN HOFFMAN, Chief Medical Officer, GE Energy
REZA JAFARI, Chairman and CEO, e-Development International (from January 2016)
JAMES JONES, Manager, Community Investment Programs, ExxonMobil
ALLISON TUMMON KAMPHUIS, Leader, Children’s Safe Drinking Water Program, Social Sustainability, Procter & Gamble Co.
ROSE STUCKEY KIRK, President, Verizon Foundation
SEEMA KUMAR, Vice President, Global R&D Communications, Johnson & Johnson
AMBASSADOR JOHN E. LANGE, Senior Fellow, Global Health Diplomacy, United Nations Foundation
NANCY MAHON, Senior Vice President, Global Philanthropy and Corporate Citizenship, Estée Lauder Companies
EDUARDO MARTINEZ, President, UPS Foundation
MICHAEL MYERS, Managing Director, The Rockefeller Foundation
REGINA RABINOVICH, ExxonMobil Malaria Scholar in Residence, Harvard T.H. Chan School of Public Health
SCOTT C. RATZAN, Vice President, Global Corporate Affairs, Anheuser-Busch InBev
B.T. SLINGSBY, Chief Executive Officer and Executive Director, Global Health Innovative Technology Fund
KATHERINE TAYLOR, Research Professor, Director of Operations, Eck Institute for Global Health, University of Notre Dame
WENDY TAYLOR, Director, Center for Accelerating Innovation and Impact, U.S. Agency for International Development
MARY LOU VALDEZ, Associate Commissioner for International Programs, Director, Office of International Programs, U.S. Food and Drug Administration
JACK WATTERS, Vice President for External Medical Affairs, Pfizer, Inc. (until July 2015)
HOLLY WONG, Principal Deputy Assistant Secretary for Global Affairs, U.S. Department of Health and Human Services
DEREK YACH, Chief Health Officer, The Vitality Group
TADATAKA “TACHI” YAMADA, Chief Medical and Scientific Officer, Executive Vice President, Takeda Pharmaceuticals (until June 2015); Venture Partner, Frazer Healthcare Partners
IOM Staff
RACHEL M. TAYLOR, Program Officer
FRANCIS AMANKWAH, Research Associate (from January 2016)
PRIYANKA NALAMADA, Research Assistant
FAYE HILLMAN, Financial Officer
PATRICK KELLEY, Director, Board on Global Health
This page intentionally left blank.
Reviewers
This workshop summary has been reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise. The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published workshop summary as sound as possible and to ensure that the workshop summary meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the process. We wish to thank the following individuals for their review of this workshop summary:
LOLA ADEDOKUN, Doris Duke Foundation
MUSHTAQUE CHOWDHURY, BRAC
MARION JACOBS, University of Cape Town
ANDREW JONES, Tropical Health and Education Trust
Although the reviewers listed above have provided many constructive comments and suggestions, they did not see the final draft of the workshop summary before its release. The review of this workshop summary was overseen by David R. Challoner, University of Florida. He was responsible for making certain that an independent examination of this workshop summary was carried out in accordance with institutional procedures and that all review comments were carefully considered. Responsibility for the final content of this workshop summary rests entirely with the rapporteurs and the institution.
This page intentionally left blank.
Acknowledgments
The National Academies of Sciences, Engineering, and Medicine’s Forum on Public–Private Partnerships for Global Health and Safety (PPP Forum) has been established to illuminate opportunities that strengthen the role of public–private partnerships (PPPs) in meeting the health and safety needs of individuals and communities around the globe. The PPP Forum seeks to foster a collaborative community of multisectoral health and safety leaders to leverage the strengths of varying sectors and multiple disciplines to yield benefits for global health and safety.
A number of individuals contributed to the development of this workshop and report. These include a number of staff members from the Institute of Medicine (IOM) and the Academies: Marton Cavani, Greta Gorman, Faye Hillman, Patrick Kelley, Sarah Kelley, Priyanka Nalamada, Bettina Ritter, Kimberly Scott, and Rachel Taylor. The planning committee contributed several hours of service to develop and execute the agenda. Reviewers also provided thoughtful remarks in reading the draft manuscript.
The overall successful functioning of the forum and its activities depends on the generosity of its sponsors. Financial support for this activity was provided by Anheuser-Busch InBev; Becton, Dickinson and Company; The Bill & Melinda Gates Foundation; CARE USA; Catholic Health Association of the United States; e-Development International; Estée Lauder Companies; ExxonMobil; Fogarty International Center of the National Institutes of Health; GE; Global Health Innovative Technology Fund; Johnson & Johnson; Lockheed Martin Corporation; Medtronic;
Merck; Novartis Foundation; PATH; PepsiCo; Pfizer, Inc.; Procter & Gamble Co.; The Rockefeller Foundation; Takeda Pharmaceuticals; United Nations Foundation; University of Notre Dame; UPS Foundation; U.S. Agency for International Development; U.S. Department of Health and Human Services Office for Global Affairs; U.S. Department of State/Office of the Global AIDS Coordinator; U.S. Food and Drug Administration; Verizon Foundation; and The Vitality Group.
Contents
Evolution of Public–Private Partnerships and Health Systems Strengthening
3 MULTISTAKEHOLDER PERSPECTIVES ON PUBLIC–PRIVATE PARTNERSHIPS FOR HEALTH SYSTEMS STRENGTHENING
Public-Sector Perspective from the Chilean National Health System
Private-Sector Perspective from Becton, Dickinson and Company
Public-Sector Perspective from Experience with the UK Department for International Development
4 PROMISING INNOVATIONS AND MODELS
Examples of Innovative Partnerships for Health Systems Strengthening
Innovative Models for Health Systems Strengthening from Narayana Health
5 LESSONS FROM PARTNERSHIP EXPERIENCES
6 MEASURING PERFORMANCE AND PROGRESS IN PUBLIC–PRIVATE PARTNERSHIPS FOR HEALTH SYSTEMS STRENGTHENING
Developing Metrics for Health Systems
Metrics for Public–Private Partnerships Focused on Health Systems Strengthening
7 SUSTAINING AND INCREASING LONG-TERM INVESTMENTS IN HEALTH SYSTEMS
Sustainable Financing for Health Systems
The Role of the Public Sector in Sustaining Partnerships for Health Systems Strengthening
Scaling Up and Sustaining Partnerships for Human Resources for Health
Community Ownership as a Model for Sustainability
A A REVIEW OF PUBLIC–PRIVATE PARTNERSHIP ACTIVITIES IN HEALTH SYSTEM STRENGTHENING
